Alnylam Pharmaceuticals falls amid broader market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2024
0mins
Should l Buy ALNY?
Source: Yahoo Finance
Alnylam Pharmaceuticals Inc. experienced a price decline of 5.24%, crossing below its 5-day SMA, reflecting a challenging trading environment.
This decline is attributed to broad market weakness, with the Nasdaq-100 down 0.69% and the S&P 500 down 0.03%. The overall market sentiment has shifted, impacting stocks across various sectors, including biotechnology.
The implications of this movement suggest that investors are cautious, potentially reallocating their portfolios in response to market conditions, which may lead to further volatility in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 322.380
Low
351.00
Averages
479.53
High
580.00
Current: 322.380
Low
351.00
Averages
479.53
High
580.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $107.43 per share, with a high of $179.64, and the current trading price at $171.83 indicates volatility near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper technical insights, aiding in market trend assessment and potential buy or sell timing.
- ETF Unit Trading Mechanism: ETF units can be traded like stocks and can be created or destroyed based on investor demand, providing flexibility that allows ETFs to better adapt to market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights significant inflows or outflows, which not only impacts the overall performance of the ETF but may also directly affect the individual stocks held within it.
See More
BridgeBio's Promising Biotech Pipeline Highlighted by William Blair
- Unique Market Position: Analyst John Boyle highlights BridgeBio's unique position with the accelerating launch of Attruby and near-term NDA submissions, setting the stage for late-2026/early-2027 launches in the rare genetic disease treatment market.
- Product Competitive Edge: Market surveys indicate that prescribers view both Attruby and Amvuttra as superior to Pfizer's Tafamidis, which has approximately $6 billion in annual sales, suggesting that BridgeBio's products are gaining traction in clinical applications.
- Sales Forecast and Risks: The analyst models U.S. sales of Attruby reaching $3.4 billion by 2035, while acknowledging potential generic entry risks in late 2028; however, Attruby's strong TTR stabilization and simple twice-daily dosing could justify premium pricing.
- Other Market Opportunities: BridgeBio also sees significant market opportunities with other rare disease drugs, particularly infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1, with the latter achieving its primary endpoint in the CALIBRATE Phase 3 study in October 2025, indicating strong future prospects.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tenaya Therapeutics Partners with Alnylam for Genetic Research
- Collaboration Agreement: Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals focused on identifying genetic targets for cardiovascular diseases, with Tenaya set to validate up to 15 gene targets and potentially receive $10 million upfront and up to $1.13 billion in milestone payments, significantly enhancing its research capabilities.
- Technical Advantages: Tenaya employs human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for high-throughput genetic target identification, alongside engineered heart tissue and preclinical in vivo models for validation, having generated over 150 genetic targets that contribute to the development of clinical-stage candidates.
- Clinical Trial Progress: In December 2025, Tenaya shared interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease, reporting safety, biopsy, and arrhythmia results from three patients, indicating the therapy's potential in treating such conditions.
- Market Performance Analysis: Despite a 31.20% increase to 76 cents, Tenaya's stock remains 29.1% and 23.6% below its 100-day and 200-day simple moving averages, indicating a bearish trend in the medium to long term, with analysts generally rating it as a
See More
Tenaya Therapeutics Partners with Alnylam for Up to $1.1B Cardiovascular Drug Collaboration
- Collaboration Agreement: Tenaya Therapeutics has signed a research collaboration with Alnylam Pharmaceuticals worth up to $1.1 billion, aimed at discovering 15 genetic targets associated with cardiovascular diseases, showcasing the company's strong potential in the biotech sector.
- Upfront Payment and Milestone Rewards: Under the terms, Tenaya will receive up to $10 million as an upfront payment and is eligible for an additional $1.13 billion based on development and commercial milestones, significantly enhancing the company's liquidity and supporting its R&D activities.
- Strategic Importance: CEO Faraz Ali emphasized that this multi-target collaboration underscores Tenaya's commitment to rigorous science and leverages its proprietary capabilities to drive the discovery and development of cardiovascular candidates, further solidifying its position in the biopharmaceutical industry.
- Positive Market Reaction: Following the announcement of the collaboration, Tenaya's stock rose approximately 10% in premarket trading, reflecting investor optimism regarding the potential of this partnership, which may enhance the company's market recognition and future growth prospects.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $107.43 per share, with a high of $179.64, and the current trading price at $171.83 indicates volatility near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper technical insights, aiding in market trend assessment and potential buy or sell timing.
- ETF Unit Trading Mechanism: ETF units can be traded like stocks and can be created or destroyed based on investor demand, providing flexibility that allows ETFs to better adapt to market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights significant inflows or outflows, which not only impacts the overall performance of the ETF but may also directly affect the individual stocks held within it.
See More
BridgeBio's Promising Biotech Pipeline Highlighted by William Blair
- Unique Market Position: Analyst John Boyle highlights BridgeBio's unique position with the accelerating launch of Attruby and near-term NDA submissions, setting the stage for late-2026/early-2027 launches in the rare genetic disease treatment market.
- Product Competitive Edge: Market surveys indicate that prescribers view both Attruby and Amvuttra as superior to Pfizer's Tafamidis, which has approximately $6 billion in annual sales, suggesting that BridgeBio's products are gaining traction in clinical applications.
- Sales Forecast and Risks: The analyst models U.S. sales of Attruby reaching $3.4 billion by 2035, while acknowledging potential generic entry risks in late 2028; however, Attruby's strong TTR stabilization and simple twice-daily dosing could justify premium pricing.
- Other Market Opportunities: BridgeBio also sees significant market opportunities with other rare disease drugs, particularly infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1, with the latter achieving its primary endpoint in the CALIBRATE Phase 3 study in October 2025, indicating strong future prospects.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Tenaya Therapeutics Partners with Alnylam for Genetic Research
- Collaboration Agreement: Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals focused on identifying genetic targets for cardiovascular diseases, with Tenaya set to validate up to 15 gene targets and potentially receive $10 million upfront and up to $1.13 billion in milestone payments, significantly enhancing its research capabilities.
- Technical Advantages: Tenaya employs human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for high-throughput genetic target identification, alongside engineered heart tissue and preclinical in vivo models for validation, having generated over 150 genetic targets that contribute to the development of clinical-stage candidates.
- Clinical Trial Progress: In December 2025, Tenaya shared interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease, reporting safety, biopsy, and arrhythmia results from three patients, indicating the therapy's potential in treating such conditions.
- Market Performance Analysis: Despite a 31.20% increase to 76 cents, Tenaya's stock remains 29.1% and 23.6% below its 100-day and 200-day simple moving averages, indicating a bearish trend in the medium to long term, with analysts generally rating it as a
See More
Tenaya Therapeutics Partners with Alnylam for Up to $1.1B Cardiovascular Drug Collaboration
- Collaboration Agreement: Tenaya Therapeutics has signed a research collaboration with Alnylam Pharmaceuticals worth up to $1.1 billion, aimed at discovering 15 genetic targets associated with cardiovascular diseases, showcasing the company's strong potential in the biotech sector.
- Upfront Payment and Milestone Rewards: Under the terms, Tenaya will receive up to $10 million as an upfront payment and is eligible for an additional $1.13 billion based on development and commercial milestones, significantly enhancing the company's liquidity and supporting its R&D activities.
- Strategic Importance: CEO Faraz Ali emphasized that this multi-target collaboration underscores Tenaya's commitment to rigorous science and leverages its proprietary capabilities to drive the discovery and development of cardiovascular candidates, further solidifying its position in the biopharmaceutical industry.
- Positive Market Reaction: Following the announcement of the collaboration, Tenaya's stock rose approximately 10% in premarket trading, reflecting investor optimism regarding the potential of this partnership, which may enhance the company's market recognition and future growth prospects.
See More
